Replies to post #125539 on Biotech Values

[biomaven0]

I don't think cabozantinib will be approved if it does not improve overall survival, regardless of its effect on metastases.

Could you elaborate on why you believe that? Seems to me there is a clear clinical benefit if you can actually improve bone mets - they are likely the dominant cause of morbidity in most late stage prostate cancer patients.

Peter